雷贝拉唑三联5日疗法根除幽门螺杆菌的疗效观察

Observing the effect of five-day rabeprazole triple therapy for Helicobacter pylori infection

目的观察雷贝拉唑三联5日疗法根除幽门螺杆菌的疗效。方法将61例患者随机分为两组,分别给予雷贝拉唑三联治疗5d及奥美拉唑三联7d,随后两组停用抗生素,单用抗酸剂3周,于治疗后35￣42d复查胃镜HP尿素酶法及14C呼气试验。结果治疗组与对照组溃疡愈合分别为87.10%、80.00%,总有效率分别为100%、95.00%,两组治愈率和有效率比较差异均无显著性(P>0.05%)。雷贝拉唑组与对照组HP根除率分别为70.97%、66.67%,两组比较差异无显著性(P>0.05%),治疗组与对照组疼痛消失时间的比较分别为(1.3±0.8)d,(2.1±0.9)d,两组有统计学意义(P<0.05)。结论雷贝拉唑三联5日疗法的HP根除率、溃疡治愈率总有效率与奥美拉唑三联7日疗法差异无显著性。雷贝拉唑对疼痛的缓解明显快于奥美拉唑。雷贝拉唑、阿莫西林和替硝唑组成的三联5日疗法是一种短程、安全、有效符合药物经济学要求的根除HP和治疗消化性溃疡的方案。雷贝拉唑三联5日疗法治疗成本优于奥美拉唑组。

[Objective] This study was designed to observe the curative effect of rabeprazole for Helicobacter pylori infection. [Method] This study was designed as a randomized prospective single center study A total of 61 H. pylori-positive patients who had not received therapy were given either a 5-day rabeprazole regimen or a 7-day omeprazole regimen. Then only give antiaeids to two groups for three weeks instead antibiotic. Cure of the infection was assessed by endoscopy and a 14C urea breath test in 35-42 days after the completion of therapy. [Results] The peptic ulcer healing rates of the 5-day rabeprazole regimen and the 7-day omeprazole regimen were 87.1% and 80%, the efficiency rates were 100% and 95%, the therapy rates treating H.pylori were 70.97%, 66.67%. Statistical analysis did not show significant difference between the two groups. The time of eliminating pain were （1.3±0.8） days for 5-day rabeprazole-based therapy, and （2.1±0.9） days for 7-day omeprazole-based therapy, show significant difference between the two groups with statistical analysis. [Conclusions] The peptic ulcer healing rates, the efficiency rate and the therapy rates treating H.pylori did not show significant difference between the 5-day rabeprazole-based therapy and the 7-day omeprazole-based therapy. The time of eliminating pain with the 5-day rabeprazole-based therapy was much shorter than with omeprazole-based therapy. The 5-day rabeprazole based triple therapy is a short-term, effective, safe and lower-therapeutic-cost regiment for H.pylori eradication and peptic ulcer therapy. The cure-cost of 5-day rabeprazole-based therapy was much lower than the 7-day omeprazole-based therapy.